OLIMAB 60MG | My Apple Pharma

                        Anti Cancer Drug-Olimab 60mg

PRODUCT DETAILS

Brand name : Olimab 

Strength : 60mg

Active substance : Denosumab 

Manufactured by : Intas Pharmaceuticals 

Pack : I injection in a prefilled syringe

Description:

Olimab 60mg belongs to novel, fully human IgG2 monoclonal antibody especially to receptor activator of nuclear factor kappa-B ligand (RANKL), restrain bone resorption markers in patients with a difference of metastatic tumors and is being examined in multiple clinical trials for the inhibition and treatment of bone metastases.
Chemically, it exists of 2 heavy and 2 light chains. Each light chain contains of 215 amino acids.
Each heavy chain contains of 448 amino acids with 4 intramolecular disulfides.

PRESCRIBED:

Treatment for patients having postmenopausal women with osteoporosis at high risk for fracture.
Treatment for patients with increase bone mass in men at more risk for fracture getting androgen deprivation therapy for non-metastatic prostate cancer.
Treatment for patients having to increase bone mass in women at more risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.

DOSAGE

For adult :

Osteoporosis :

olimab 60mg SC (subcutaneously) once every 6 months
Injection of drug should be done in upper arm, upper thigh or abdomen
Giant Cell Tumor of bone :
120mg SC, every 4 weeks with additional 120mg doses on days 8 and 15 of the 1st month treatment
Injection of drug should be done in upper arm, upper thigh or abdomen

MECHANISM

Denosumab linked to RANKL, a protein which is specific for the formation, function and survival of osteoclasts, the cells necessary for bone resorption. Denosumab prohibits osteoclast formation, function and survival hence, reducing bone resorption and raising bone mass and strength of the bone.
Peak plasma concentration: 6.75mcg/mL
Tmax : 10days
Without aggregation in Olimab 60mg pharmacokinetics with duration was noticed upon multiple dosing of 60 mg SC administered once every 6 months.
Pharmacokinetics of Olimab will not affected by the binding antibodies formation.
Half-life is 25.4 days.

PRECAUTION:

• Before to start treatment with Olimab 60mg, discuss with the doctor about any other regimens you are using (including over-the-counter drugs, vitamins, or herbal remedies). Do not take aspirin or products containing aspirin unless your doctor permits this.
• Olimab 60mg injection may improve the negative effects of immuno-suppressants. Especially the risk for serious infections may be increased. Inform your doctor of any immuno-suppressive drugs you early consume.
• Not to receive any type of vaccination without your doctor's consultation while admonishing denosumab.
• Use in pregnancy only if benefit to mother outweighs risk to fetus. Consult with doctor before the treatment
• During Olimab 60mg treatment do not breastfeed your infants. 

DRUG INTERACTION

No formal drug-drug interaction with denosumab during trials.
When interacting with some anticancer drug, orthopedic drugs, vaccines will lead to risk of adverse effects can be increased

CONTRAINDICATION

 Olimab 60mg is contraindicated in patients having Hypocalcemia, Pregnancy, Hypersensitivity

STORAGE

Store at 2℃ to 8℃ in the original container, avoid freeze
Before to administration keep at room temperature
 Olimab 60mg protect from direct light and heat.

SIDE EFFECTS

Common side effects for the patient taking  Olimab 60mg as follows :
Fatigue, Muscle weakness, Phosphorus level reduced in blood, Nausea
Less common side effects for patients taking Olimab :
Dyspnea, Hypocalcemia, Cough, Arthralgia, Limb pain, Eczema, Headache

MISSED DOSE

Take the  Olimab 60mg dose immediately before next dose duration, then left off the missed dose and continue regular schedule. Avoid taking double dose at same time.
Please consult the doctor for further information.

Contact Details

Phone :+91-9987711567

Email :applepharmaceutical@gmail.com

Email :info@myapplepharma.com